Join the Diabetes, Type 2 group to help and get support from people like you.
Diabetes, Type 2 News (Page 15)
Related terms: Noninsulin-dependent Diabetes, Type 2 Diabetes, Diabetes, Type 2
Timed Fasting Best Way for Those With Diabetes to Lose Weight
MONDAY, July 24, 2023 – Restricting eating to certain times – a regimen known as intermittent fasting – may be the best way to help people with type 2 diabetes lose weight. Researchers found that...
FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes
June 20, 2023 – Today, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve...
FDA Approves Jardiance (empagliflozin) for the Treatment of Type 2 Diabetes in Children 10 Years and Older
RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along...
FDA Medwatch Alert: FDA Issues Warning About Compounded Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
On May 30, 2023, the FDA posted information about medications containing semaglutide marketed for type 2 diabetes or weight loss. There are currently three FDA-approved semaglutide products which are...
FDA Approves Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
MARLBOROUGH, Mass.--(BUSINESS WIRE) January 23, 2023 --TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy (bexagliflozin), an oral sodium-glucose...
Novo Nordisk Announces FDA Approval of Label Update for Rybelsus (semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes
People living with type 2 diabetes can now take Rybelsus®, the first and only oral glucagon-like peptide-1 (GLP-1) analog, along with diet and exercise, as initial therapy to help lower their A1C1,2 ...
Lyumjev (insulin lispro-aabc) Injection Approved by U.S. FDA for Children with Diabetes
October 14, 2022 – The U.S. Food and Drug Administration (FDA) approved an expansion of the indication for Eli Lilly and Company's rapid-acting mealtime insulin Lyumjev® (insulin lispro-aabc) ...
FDA Medwatch Alert: Mylan Pharmaceuticals Inc. Issues Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection Pens U-100, Due to the Potential of Missing Labels on Some Pens
PITTSBURGH – July 5, 2022 – Mylan Pharmaceuticals Inc., a Viatris company, is voluntarily recalling one batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL pre...
FDA Approves Mounjaro (tirzepatide) Injection for the Treatment of Adults with Type 2 Diabetes
INDIANAPOLIS, May 13, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP...
FDA Medwatch Alert: Mylan Issues Voluntary Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), Due to the Potential for a Missing Label
April 12, 2022 – Mylan Pharmaceuticals Inc., a Viatris company, is voluntarily recalling one batch of its Insulin Glargine (Insulin glargine- yfgn) Injection, 100 units/mL (U-100), which is packaged i...
Novo Nordisk Receives FDA Approval of Higher-Dose Ozempic 2 mg Providing Increased Glycemic Control for Adults with Type 2 Diabetes
Ozempic® demonstrated 2.1% blood sugar reduction and also weight loss in adults with type 2 diabetes with new 2 mg dose1 PLAINSBORO, N.J., March 28, 2022 /PRNewswire/ – Novo Nordisk today ...
Bydureon BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
WILMINGTON, Del.--(BUSINESS WIRE) July 23, 2021--AstraZeneca’s Bydureon BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 d...
FDA Approves Lyumjev (insulin lispro-aabc injection) 100 units/mL for Use in Insulin Pumps
INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY) rapid-acting insulin, Lyumjev (insulin...
FDA Approves Semglee (insulin glargine-yfgn) as the First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes
SILVER SPRING, Md., July 28, 2021 /PRNewswire/ – Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in a...
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
WHIPPANY, N.J.-- July 9, 2021 (BUSINESS WIRE)-- Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
metformin, Ozempic, Victoza, Lantus, Mounjaro, Trulicity, glipizide, semaglutide, Rybelsus, view more... Lantus Solostar, Humalog, Farxiga, Novolog, Jardiance, Janumet, insulin glargine, Januvia, insulin lispro, Bydureon, Tresiba, Levemir, liraglutide, Invokana, Glucophage, Humulin N, insulin degludec